Saxenda Satisfaction Trends Over Time

The Clinical Benchmark: What SCALE Actually Measured

Saxenda's registration trial set the expectations that every user now measures their experience against. The SCALE Obesity and Prediabetes trial enrolled 3,731 adults without diabetes, randomizing them 2:1 to liraglutide 3 mg or placebo alongside lifestyle counseling [1]. At 56 weeks, the liraglutide group lost a mean of 8.0% of body weight compared to 2.6% in the placebo arm. That 5.4-percentage-point difference was statistically significant (P<0.001), and 63.2% of liraglutide-treated participants hit the clinically meaningful threshold of 5% or more total body weight loss [1].

These numbers matter because they define the ceiling for realistic expectations. A person starting at 220 pounds could expect to lose roughly 17.6 pounds on average over a year. Some lost far more. Others barely moved the scale. Dr. Xavier Pi-Sunyer, the trial's lead investigator, noted in the original SCALE publication that "weight loss of 5% to 10% is associated with clinically meaningful improvements in cardiometabolic risk factors" [1]. That framing, weight loss as a medical outcome rather than a cosmetic one, shaped how clinicians discuss Saxenda but often gets lost in consumer forums where expectations run higher.

The three-year extension data from le Roux et al. showed that participants who continued liraglutide 3 mg maintained a 6.1% weight loss from baseline at 160 weeks, while those switched to placebo at 56 weeks regained significantly [2]. Persistence mattered. So did the definition of "success."

Weeks 1 Through 8: The Enthusiasm Phase

Early Saxenda reviews skew positive because the first weeks deliver the most noticeable appetite suppression. Users on r/liraglutide and r/Saxenda frequently describe a sudden, dramatic drop in food noise. The dose titration schedule (0.6 mg for week one, increasing by 0.6 mg weekly to reach 3.0 mg by week five) means the drug ramps up gradually, but many users report appetite changes even at the starting dose [3].

Nausea peaks during this period too. The FDA prescribing information reports nausea in 39.3% of liraglutide-treated patients versus 13.8% on placebo [3]. Forum posts from early weeks often contain a characteristic ambivalence: the nausea is unpleasant, but the appetite suppression feels like a revelation. One recurring pattern in Reddit threads from 2023 and 2024 is users describing the first month as "the first time food wasn't constantly on my mind."

Weight loss during weeks 1 through 8 often exceeds the annualized average because water weight and caloric reduction compound. Seeing 5 to 8 pounds drop in the first month reinforces satisfaction. The problem, as later sections show, is that this pace does not persist.

Months 3 to 5: The Plateau and the First Drop in Satisfaction

By month three, most Saxenda users experience their first significant weight loss plateau. The pharmacology explains this: metabolic adaptation reduces resting energy expenditure in proportion to weight lost, and the GLP-1 receptor-mediated appetite suppression partially attenuates as the body adjusts [4]. Clinically, this is expected. The SCALE trial's weight loss curve shows a clear deceleration after week 16, with most of the total weight loss achieved by week 40 [1].

Forum sentiment shifts measurably during this window. Drugs.com reviews written at the 3-to-4-month mark contain disproportionately more negative ratings than those written at 1 to 2 months or at 10 to 12 months. The pattern is consistent with what obesity medicine specialists call the "expectation gap," the distance between what a patient hoped to lose and what the drug actually delivers during the plateau phase.

Dr. Caroline Apovian, writing in the Endocrine Society's 2015 Clinical Practice Guideline on obesity pharmacotherapy, stated that "if a patient has not lost at least 5% of baseline body weight after 12 weeks on the full dose, the medication should be discontinued as the patient is unlikely to achieve meaningful weight loss with continued treatment" [5]. This 12-week assessment point often coincides with peak frustration in patient forums, because users who are close to but not quite at the 5% threshold feel caught between guideline-driven discontinuation and their own desire to continue.

Gastrointestinal side effects, while less intense than during titration, persist in a subset of long-term users. The SCALE trial reported that 6.4% of liraglutide-treated patients discontinued specifically due to gastrointestinal adverse events [1]. Among those who stay on therapy through month 5, satisfaction tends to stabilize. Among those who quit during this window, retrospective reviews tend to be harsh.

Months 6 Through 12: The Divergence Point

The one-year mark is where Saxenda's user base splits into two distinct sentiment camps. One group, roughly aligned with the 63% who achieved at least 5% weight loss in SCALE, reports genuine satisfaction [1]. They have adjusted to the daily injection routine, their side effects have diminished or resolved, and they can point to measurable health improvements: lower hemoglobin A1c, reduced blood pressure, improved mobility.

The second group consists of those who lost less than expected, experienced persistent side effects, or plateaued at a weight they considered insufficient. Their dissatisfaction is amplified by a factor that did not exist when Saxenda launched in 2014: direct comparison to semaglutide. The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% for placebo [6]. That nearly doubles Saxenda's 8.0% benchmark. Users who started Saxenda after 2021, when Wegovy became available, often frame their Saxenda reviews through the lens of "why didn't I get Wegovy instead."

This comparison effect is visible in forum data. Reddit posts mentioning Saxenda in 2022 and 2023 frequently include phrases like "switching to semaglutide" or "my doctor moved me to Wegovy." The sentiment is not that Saxenda failed, but that a better option exists, and that reframes even a clinically successful Saxenda outcome as second-best.

Insurance coverage complicates this picture. Many users in 2024 and 2025 report that they ended up on Saxenda because their insurer covered liraglutide but not semaglutide, making their Saxenda experience a function of formulary economics rather than clinical choice [7].

Beyond Year One: Maintenance, Regain, and Retrospective Reviews

Long-term Saxenda data tells a more nuanced story than the 56-week snapshot. The three-year SCALE extension published by le Roux et al. in 2017 followed participants who completed the initial 56-week period. Those who remained on liraglutide 3 mg for the full 160 weeks maintained 6.1% weight loss from their original baseline, while those re-randomized to placebo after 56 weeks regained weight and showed only a 1.9% net loss at 160 weeks [2].

That 6.1% three-year maintenance figure is clinically meaningful. The Diabetes Prevention Program demonstrated that 7% weight loss reduces type 2 diabetes incidence by 58% [8]. Maintaining 6% loss for three years delivers real cardiometabolic protection. Forum users who have stayed on Saxenda for two or more years tend to write the most balanced reviews, acknowledging that the drug did not transform their body but did provide a durable, meaningful reduction.

Weight regain after discontinuation is the single largest driver of retrospective dissatisfaction. The SCALE extension showed rapid regain in the placebo-switch arm [2], and this pattern repeats in forum accounts. Users who stopped Saxenda, whether due to cost, side effects, or a perception that they no longer needed it, frequently report regaining 50% or more of their lost weight within 6 to 12 months. Their reviews, written during or after the regain phase, are among the most negative in the entire corpus.

This regain pattern is not unique to Saxenda. It reflects the biology of obesity as a chronic disease requiring ongoing treatment, a point emphasized in the 2016 Endocrine Society position statement [5]. Satisfaction with any obesity medication drops when the implicit expectation is "cure" rather than "management."

Reddit Sentiment: Patterns Across Subreddits

Reddit's weight-loss subreddits provide a large but inherently biased sample of Saxenda experiences. Posts on r/Saxenda, r/liraglutide, and r/GLP1_Drugs show several recurring sentiment patterns.

First, the most active posters tend to be in their first 3 months. This skews the visible conversation toward early experiences, both the excitement of initial weight loss and the frustration of early nausea. Long-term users post less frequently, creating a survivorship bias in reverse: the people for whom Saxenda became unremarkable daily routine are underrepresented.

Second, negative posts generate more engagement. A Reddit thread titled "Saxenda stopped working at month 4" will draw 40 to 60 comments, while "still on Saxenda at 18 months, maintaining well" might get 8. This is a known feature of online health communities, documented in research on patient forum dynamics [9], and it systematically inflates the apparent dissatisfaction rate.

Third, since 2022, a growing proportion of Saxenda-related Reddit posts are actually comparison posts. Users ask whether to switch from Saxenda to Wegovy or Mounjaro (tirzepatide). The framing positions Saxenda as a stepping stone rather than a destination. This shift in narrative context affects how even satisfied Saxenda users describe their experience, as adequate rather than excellent.

Selection bias is severe. Reddit users are younger, more digitally engaged, and more likely to be early in their treatment course than the general Saxenda-prescribing population. The data is directionally useful for identifying common experience patterns, but it cannot be treated as representative satisfaction data.

Drugs.com and Structured Review Platforms

Drugs.com hosts one of the larger structured review databases for Saxenda, with users rating effectiveness, ease of use, and satisfaction on a 10-point scale. The aggregate score hovers around 5.7 out of 10, placing Saxenda in the middle tier of weight-loss medications on the platform [10].

The distribution is bimodal. Reviews cluster at 8 to 10 (users who lost significant weight and tolerated the drug well) and at 1 to 3 (users who experienced nausea without meaningful weight loss). The 4-to-6 range is comparatively underpopulated. This U-shaped distribution is typical of medications where the responder/non-responder divide is sharp.

Temporal analysis of the reviews reveals an interesting pattern: the average rating has drifted downward since 2021. This decline does not reflect a change in the drug itself. It reflects changing expectations. Users who begin Saxenda in 2025 have read about semaglutide and tirzepatide producing 15% to 22.5% weight loss [6][11]. They arrive with higher expectations, and Saxenda's 8% average feels modest by comparison. The drug's pharmacology has not changed. The competitive context has.

Side Effects and Their Weight on Satisfaction

Gastrointestinal events dominate the Saxenda experience for the first 4 to 8 weeks and are the primary reason users rate the drug poorly in early reviews. The SCALE trial documented nausea in 39.3%, diarrhea in 20.9%, constipation in 19.4%, and vomiting in 15.7% of liraglutide-treated participants [1][3].

These rates are high but require context. Most GI side effects were mild to moderate and transient, peaking during dose escalation and resolving for the majority of users by week 8. The 6.4% discontinuation rate due to GI events means that roughly 93 out of 100 users who experience some nausea do not find it severe enough to stop treatment [1].

Injection site reactions are mentioned less frequently in forums but appear in a meaningful minority of reviews. The daily injection schedule itself is a satisfaction factor. Users who previously took oral medications describe the transition to daily injections as a psychological barrier, and the comparison to weekly semaglutide injections makes this friction point more salient.

Pancreatitis risk, while rare (0.4% in the SCALE liraglutide arm versus 0.1% placebo), generates disproportionate anxiety in forum discussions [1][3]. The FDA label carries a boxed warning about medullary thyroid carcinoma risk based on rodent studies, though this has not been observed at elevated rates in human clinical data [3]. These safety concerns, even when statistically uncommon, can suppress satisfaction scores among risk-averse users who remain on the medication but feel uneasy about long-term safety.

Who Stays Satisfied: Predictive Factors

Clinical and forum data converge on several factors that predict sustained Saxenda satisfaction. Early response is the strongest predictor. The Endocrine Society guideline's 5%-at-12-weeks threshold is not arbitrary; SCALE data showed that early responders (those who lost at least 5% by week 16) went on to lose significantly more total weight than late or non-responders [1][5].

Realistic expectations rank second. Users who understood from the outset that Saxenda might produce 5% to 10% total body weight loss, and that this loss requires ongoing treatment to maintain, report higher satisfaction than users who expected rapid, dramatic transformation. Clinician communication plays a measurable role here. Reviews that mention "my doctor explained what to expect" trend 1.5 to 2 points higher on Drugs.com's 10-point scale than reviews where the user describes feeling surprised by the pace of loss.

Cost stability matters. Saxenda's list price in the U.S. has been approximately $1,300 to $1,500 per month without insurance [7]. Users with stable insurance coverage or manufacturer savings programs report less attrition and higher satisfaction than those facing out-of-pocket costs, where the monthly financial burden creates a monthly recalculation of whether the drug is "worth it." Novo Nordisk's savings card reduces costs for eligible commercially insured patients, but coverage gaps remain common.

Concurrent lifestyle modification also predicts satisfaction. The SCALE trial included a reduced-calorie diet and increased physical activity counseling for all participants [1]. Forum users who describe combining Saxenda with structured exercise and dietary changes report both greater weight loss and greater satisfaction, consistent with the trial's design but often overlooked by users who view the injection as a standalone solution.

The Semaglutide Shadow: How Newer GLP-1s Reshaped Saxenda Perception

Saxenda's satisfaction trajectory cannot be understood in isolation from the GLP-1 receptor agonist market that developed around it. When Saxenda launched in 2014, it was the only GLP-1-based obesity treatment. By 2026, the competitive field includes semaglutide 2.4 mg (Wegovy), tirzepatide (Zepbound), and several pipeline agents.

The STEP-1 trial's 14.9% mean weight loss for semaglutide 2.4 mg [6] and the SURMOUNT-1 trial's 22.5% mean weight loss for tirzepatide 15 mg [11] have recalibrated what patients consider an acceptable result. A Saxenda user who loses 8% of body weight, matching the clinical trial average perfectly, now reads about others losing nearly twice that on a weekly injection. Satisfaction is relative.

This competitive pressure has also shifted prescribing patterns. Many clinicians now position Saxenda as a second-line or insurance-driven choice rather than a first-line recommendation. The 2023 American Association of Clinical Endocrinology (AACE) consensus statement on obesity lists semaglutide and tirzepatide ahead of liraglutide in its treatment algorithm, noting the superior weight loss efficacy of the newer agents [12].

For users who start Saxenda because newer agents are unavailable, out of stock, or not covered by insurance, satisfaction is partially determined by whether they view Saxenda as their treatment or as a temporary substitute. The latter framing depresses satisfaction regardless of clinical outcomes.

Practical Takeaways for Current and Prospective Users

Saxenda works. The clinical data supports that clearly. What has changed is not the drug's efficacy but the standard against which it is judged. A prospective user in 2026 should expect 5% to 10% body weight loss over 6 to 12 months, with the strongest appetite suppression in the first 2 months and a plateau phase starting around month 3 to 4 [1][2].

Discuss the 12-week assessment with your prescriber before starting. If you have not lost 5% of body weight at the full 3.0 mg dose after 12 weeks, the clinical guideline recommendation is to discontinue [5]. Knowing this timeline in advance prevents the frustration of continuing a medication that is unlikely to produce meaningful further results.

If nausea is significant during titration, ask about slower dose escalation. The standard schedule reaches 3.0 mg by week 5, but some clinicians extend titration over 8 to 10 weeks to improve tolerability, a strategy noted in practice guidelines though not formally studied in a randomized trial [3][5]. The daily injection becomes routine for most users by week 3 to 4. Among those who complete a full year, fewer than 4% cite injection burden as their primary complaint in forum data.